Fig. 3: TIGIT expression, methylation, and survival probabilities in AML. | npj Precision Oncology

Fig. 3: TIGIT expression, methylation, and survival probabilities in AML.

From: Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy

Fig. 3

a The survival probability curves for TIGIT in AML patients, comparing high and low TIGIT expression groups. The p-values (p = 0.0016 and p = 0.013) indicate statistically significant differences in survival between the groups. b The mutation count distribution across different sample groups (LowExp and HighExp) for various genes. The bar chart shows the percentage of mutations for each gene, highlighting the differences between the groups. c The UMAP plots represent the clustering of AML samples at different time points (D0, D14, D15, D18) and overall (Before and After). The plots show the distribution and changes in cell populations over time. d TIGIT expression levels across different clinical stages (Initial Diagnosis, Residual, Remission, Relapse, Unknown). The p-value (p = 0.018) indicates a significant difference in TIGIT expression between these stages. e The methylation patterns of genes related to the TIGIT group, showing variations in methylation levels across different samples. f The methylation status of the TIGIT gene promoter and gene body in remission and initial diagnosis samples. Green dots represent methylated regions, while empty dots represent unmethylated regions. g The methylation rates between remission and initial diagnosis samples, showing the distribution and differences in methylation levels.

Back to article page